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All contemporary general anaesthetics has have been convincingly shown to produce 
neurotoxic effects in at least some experimental animal models and many of the underlying 
mechanisms have been identified.1 Whilst the human relevance of these observations is still 
under intense scrutiny, elaboration of protective strategies along with the development of 
new “non-toxic” anaesthetic drug regimens have been identified as rational research 
directions to alleviate potential neurotoxicity.2 In this edition of the journal Atlury and 
colleagues report preliminary animal experiments with a novel neurosteroid hypnotic.3 They 
describe the compound as “safe” in comparison to ketamine and suggest that a new class of 
hypnotic ‘a distinct panselective T-channel blocker devoid of GABAergic or NMDA 
antagonistic properties at hypnotically-relevant brain concentrations’ represents a rational 
route of drug development which might provide effective anaesthesia without paediatric 
neurotoxicity.  
This work deserves particular attention since it provides us with the detailed laboratory 
neurotoxicity profile of a drug, 3-OH , that can induce anaesthesia/sedation comparable to 
that of ketamine.  Focusing on 7-day-old neonatal rat pups, the authors first showed that 3-
OH is virtually devoid of pro-apoptotic effects when compared to ketamine at equipotent 
concentrations. In line with these observations, they then provide us with data showing that, 
unlike ketamine, neonatal administration of 3-OH will not lead to impaired spatial learning 
at later stages of life in this experimental model. In parallel, the authors also performed serial 
measurements of 3-OH concentrations both in the plasma and the brain to obtain 
pharmacokinetic profiles of this drug. Finally, they performed a series of electrophysiological 
recordings to identify potential targets and find that 3-OH is a potent T-channel blocker but 
lacks direct effects on both GABA- and NMDA-mediated-currents. 
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What do these new and interesting data teach us? Can we consider, as the authors suggest, 
that this “novel class of anaesthetic agents with different cellular targets might be safe and 
promising alternatives to the traditional general anesthetics currently used in pediatric 
medicine”? Whilst this hypothesis is definitely plausible, there is still a long way to go to reach 
such a conclusion with sufficient certainty.  
From the pre-clinical perspective, the major question is what criteria should be fulfilled in 
order to declare drug safety as far as the neurotoxicity issue is concerned? There is obviously 
no appropriate answer to this question. By performing a large pallet of experimental 
approaches, Atlury et al., clearly raise the standards on how to describe neurotoxicity 
potential of new compounds.3 Based on their observations, we have a reasonable set of 
arguments to consider that 3-OH is less toxic then ketamine in this particular experimental 
model. However, we cannot exclude that 3-OH induces a variety of other morpho-functional 
effects at this particular or at another developmental stage which, in turn, could induce 
neurocognitive deficits at distinct cognitive domains that are not tested with the behavioural 
paradigm applied in this study. To push this reflection further toward translational relevance, 
future experiments on the neurotoxicity profile of this drug are needed in the context of 
surgery and analgesia. Should the authors or other investigators perform these experiments 
in the future before taking 3-OH toward clinical trials? To answer this question, it should be 
remembered that none of the currently used anaesthetics drugs have been undergone such 
detailed testing protocols. Knowing the costs associated with such experiments, especially in 
light of as yet dubious clinical relevance, it is difficult to envisage that such detailed preclinical 
work will ever be conducted on all currently used anaesthetics. Last but not least, results 
obtained by one research group should be reproduced by other laboratories before taking 
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the observations for granted. This latter point is important to emphasize especially when 
considering two recent studies where performing the very same experimental protocol to 
evaluate the neurotoxic potential of dexmedetomidine yielded largely divergingent results. 
4,5  
From the clinical perspective, all contemporary general anaesthetics produce neurotoxic 
effects in at least some animal or model system and it is this rather than convincing human 
data that have precipitated precautionary comments by regulators.6 Anaesthesia providers 
are currently confronted by a “problem” i.e. alleged neurotoxicity risk to paediatric recipients 
of general anaesthesia whilst not having any robust basis on which to choose one anaesthetic 
against another. Nevertheless, research in this area has been identified as an international 
priority and outcomes from human studies are eagerly awaited. 
Anaesthetic effects on cancer outcomes, paediatric neurotoxicity and propensity to post-
operative cognitive dysfunction in adult patients have been recommended as new 
development targets for hypnotic development programs7 and it is against this background 
we should consider neuroactive steroid, 3β-OH [(3β,5β,17β)-3-hydroxyandrostane-17-
carbonitrile]. 
Are preclinical studies a useful guide to neurotoxic propensity in children and neonates? Quite 
clearly the answer is that we currently have no idea. Given the uncertain relevance of 
preclinical data to humans then the conduct of additional animal experiments as is unlikely 
to take us any further forward. What we need to know is whether a drug is safe in humans. 
Easy to say but difficult to do. If the only valid model for demonstration of anaesthetic 
neurotoxicity in humans is the demonstration of anaesthetic neurotoxicity in humans then 
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we are not going to make much progress except through lengthy, expensive and hard to 
conduct randomised controlled trials. 
From a practical standpoint, the “elephant in the room” affecting the development of new 
hypnotics is the ubiquitous availability of low-cost and safe intravenous anaesthesia using 
generic propofol formulations. Although there are well known issues with propofol 
(specifically, the lipid formulation, the risks of bacterial contamination and subsequent sepsis, 
pain on injection and cardiorespiratory depression), the reality is that virtually every patient 
may be safely anaesthetised using propofol subject to judicious choice of dosing and 
appropriate use of fluid and pressors.8 Any new hypnotic therefore has its business case 
substantially undermined by the presence in the marketplace of an excellent low-cost generic 
competitor. For a development project to make progress in the harsh commercial world the 
compound concerned will need to have a distinct “edge” over its competitors. 
In order for a putative non-neurotoxic hypnotic to complete development and approval 
followed by successful commercialisation and deployment several conditions need to be 
satisfied. Firstly, the clinical community need to be convinced that paediatric anaesthetic 
induced neurotoxicity is a reality.9 At present the data appears to suggest the opposite.10 
Whilst historic data offer some signals that early exposure to general anaesthesia might be 
associated with neurodevelopmental delay, autism or other markers of impaired brain 
function the evidence can best be summarised as equivocal and all-parties stress the 
importance of prospective randomised controlled trials.11 To date, the nonrandomised 
PANDA trial 12 has a negative outcome and we await the five year data from the randomised 
GAS study knowing as we wait that the two-year planned interim analysis showed no 
difference between patients receiving general anaesthesia and those who did not.13 Other 
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high quality clinical data can be anticipated (including the TREX trial comparing sevoflurane 
anaesthesia with a technique based mainly upon dexmedetomidine and remifentanil (albeit 
with a small amount of sevoflurane), ClinicalTrials.gov identifier: NCT02353182. Nevertheless 
it now seems very likely that none of the current limited portfolio of prospective clinical trials 
are going to show a convincing anaesthetic effect. What we do then? Would we propose to 
continue using agents known to be neurotoxic in a range of animal models? In the absence of 
an alternative the answer can easily become yes. Once we’ve identified a convincingly non-
neurotoxic (at least in animals…) hypnotic the dialogue may change, possibly in a non-rational 
manner. As scientists we could argue that is logical to continue using understood hypnotics 
that are known to be neurotoxic in animal models but appear to be harmless in humans. As 
parents we might think about it differently, preferring compounds which are not neurotoxic 
even if the known neurotoxicity either doesn’t matter to humans or doesn’t exist in them. 
Good luck to the anaesthesiologist attempting to have that conversation with anxious parents 
shortly before taking their child to the operating room! 
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